Elbasvir and grazoprevir for chronic hepatitis C genotypes 1 and 4.
During the last few years, treatment of hepatitis C virus (HCV) revolutionized with the appearance of direct antiviral agents especially for patients with HCV genotypes 1 and 4 infections. Elbasvir (NS5A inhibitor) and grazoprevir (NS3/4A protease inhibitor) are newly developed drugs that are presented in fixed dose combination tablets. Areas covered: This review covers the mechanism of action, pharmacokinetic and pharmacodynamics properties, clinical uses, safety and efficacy of elbasvir/grazoprevir in managing a wide variety of easy and difficult to treat populations (such as presence of cirrhosis, treatment experienced, co-infection with HIV and patients with inherited blood disorders). Expert commentary: Elbasvir/grazoprevir combination showed great efficacy with high rates of sustained virological response rates in genotypes 1 and 4 HCV infection. In addition, it retained a good safety profile and is generally well tolerated.
a Endemic Medicine Department, Faculty of Medicine , Helwan University , Cairo , Egypt.
Mohamed
M
El Kassas
b Endemic Hepatogastroenterology, Faculty of Medicine , Cairo University , Cairo , Egypt.
Tamer
T
Elbaz
c Tropical Medicine Department, Faculty of Medicine , Ain Shams University , Cairo , Egypt.
Yasmeen
Y
Abd El Latif
b Endemic Hepatogastroenterology, Faculty of Medicine , Cairo University , Cairo , Egypt.
Gamal
G
Esmat
D000998:Antiviral Agents / Q000008:administration & dosage* / Q000009:adverse effects / Q000494:pharmacology; D001572:Benzofurans / Q000008:administration & dosage* / Q000009:adverse effects / Q000494:pharmacology; D004338:Drug Combinations; D005838:Genotype; D016174:Hepacivirus / Q000187:drug effects / Q000235:genetics / Q000302:isolation & purification; D019698:Hepatitis C, Chronic / Q000188:drug therapy* / Q000821:virology; D006801:Humans; D007093:Imidazoles / Q000008:administration & dosage* / Q000009:adverse effects / Q000494:pharmacology; D011810:Quinoxalines / Q000008:administration & dosage* / Q000009:adverse effects / Q000494:pharmacology
D000998:Antiviral Agents; D001572:Benzofurans; D004338:Drug Combinations; D007093:Imidazoles; D011810:Quinoxalines; C000611265:elbasvir-grazoprevir drug combination
HCV; elbasvir and grazoprevir; genotype 1; genotype 4